OxyLo
Defeating cancer from the inside out
At a glance
-
Development stage
Prototype developed
-
Investment stage
Pre-Seed
-
UNSW affiliation
Spinout - staff led
-
Technology readiness level
TRL 5
OxyLo is developing a targeted cancer treatment designed to deliver chemotherapy directly at the tumour.
-
OxyLo’s ProCaps are biodegradable microspheres loaded with enzymes and delivered into the tumour’s blood supply during a standard embolization. It combines two FDA approved treatment modalities in one: (1) ProCaps first block tumour blood supply, starving the cancer; and (2), the patient then takes an inert oral prodrug which the enzyme converts into potent chemotherapy only at the tumour, and only when dosed. ProCaps will be reimbursed as a drug, supporting roughly 90% gross margins.
-
Most chemotherapeutics are toxic to more than just the cancer cells, leading to a range of harmful side effects in patients. Even locoregional therapies like trans-arterial embolization leak cytotoxic drugs into the bloodstream and reach only part of a tumour, forcing clinicians to under-dose.
-
Interventional radiologists and oncologists performing liver-directed (TACE) procedures, and the hospitals funding them. Long term, pharmaceutical and med device partners as commercialization or acquisition routes.
-
- Awarded NIH SBIR Fast-Track grant (approximately US$1.5M)
- Second PCT patent filed on ProCaps methodology
- In vitro validation and in vivo proof-of-concept, >60% tumour reduction
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.